Nicola Farina

Nicola Farina

Auto-generated profile, based on publicly available information

Nicola Farina

Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital , Milan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2020 in The Lancet Rheumatology
Verified
Journal Article
Closed access
GCGiulio Cavalli
Giulio Cavalli
GLGiacomo De Luca
Giacomo De Luca
CCCorrado Campochiaro
Corrado Campochiaro
EDEmanuel Della-Torre
Emanuel Della-Torre
MRMarco Ripa
Marco Ripa
LDLorenzo Dagna
Lorenzo Dagna

3 February 2020 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
LMLuca Moroni
Luca Moroni
NFNicola Farina
Nicola Farina
LDLorenzo Dagna
Lorenzo Dagna

15 May 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
SMSara Monti
Sara Monti
AMAlessandra Milanesi
Alessandra Milanesi
CKCatherine Klersy
Catherine Klersy
ATAlessandro Tomelleri
Alessandro Tomelleri
LDLorenzo Dagna
Lorenzo Dagna
GBGiacomo Bagni
Giacomo Bagni
Background Immune and vascular ageing are proposed risk factors for giant cell arteritis (GCA). Data on the impact of age at diagnosis of GCA on the clinical presentation and course of the disease are scarce. Methods Patients with GCA followed at referral centres within the Italian Society of Rheumatology Vasculitis Study Group were enrolled up to November 2021. Patients were grouped according to age at diagnosis: ≤64, 65–79 and ≥80 years old. Results The study included 1004 patients, mean age 72.1±8.4, female 70.82%. Median follow-up duration was 49 (IQR 23–91) months. Patients in the oldest group (≥80 years) had significantly more cranial symptoms, ischaemic complications and risk for blindness compared with the groups 65–79 and ≤64 years (blindness: 36.98% vs 18.21% vs 6.19%; p65 years old had 2–3 fold increased risk for aortic aneurysm/dissection up to 60 months follow-up. Serious infections, but not other treatment-related complications (hypertension, diabetes, osteoporotic fractures), were significantly associated with older age. Mortality occurred in 5.8% of the population with age >65, cranial and systemic symptoms as independent risk factors. Conclusions The highest risk of ischaemic complications, aneurysm development, serious infections and the possible undertreatment make of GCA a very challenging disease in the oldest patients.

4 November 2022 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
NFNicola Farina
Nicola Farina
ATAlessandro Tomelleri
Alessandro Tomelleri
CCCorrado Campochiaro
Corrado Campochiaro
LDLorenzo Dagna
Lorenzo Dagna

1 January 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
Corrado CampochiaroCorrado Campochiaro
Corrado Campochiaro
GCGiulio Cavalli
Giulio Cavalli
NFNicola Farina
Nicola Farina
ATAlessandro Tomelleri
Alessandro Tomelleri
GLGiacomo De Luca
Giacomo De Luca
LDLorenzo Dagna
Lorenzo Dagna

12 May 2023 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Open access
NFNicola Farina
Nicola Farina
JWJemma Webster
Jemma Webster
WLWeike Luo
Weike Luo
DGDaniela Garelick
Daniela Garelick
SPSara Moreira Pinto
Sara Moreira Pinto
ARAnisur Rahman
Anisur Rahman
Systemic lupus erythematosus (SLE) is associated with an increased cardiovascular risk. Several traditional and disease-specific risk factors have been shown to correlate with the occurrence of cardiovascular events (CVE) in patients with SLE. However, results of previous studies are diverse. The objectives of this study were to report number, type and those factors associated with CVE in patients with SLE in a large, single-center, ethnically diverse cohort with a long follow-up duration. Medical records of patients treated at the Lupus Clinic at University College London Hospital (UCLH) between 1979 and 2020 were retrospectively reviewed. Data about CVE, traditional cardiovascular risk factors, demographic and disease features, and treatment history were collected. Only patients with complete available information were included in the study. Regression analyses were performed to identify factors associated with CVE. Four hundred and nineteen patients were included in the study. Maximum follow-up length was 40 years. Seventy-one (17%) patients had at least one CVE. Multivariable analysis showed that only antiphospholipid antibody positivity (p-value<0.001) was associated with CVE. When analysing different types of CVE, antiphospholipid antibodies were specifically associated with both venous thromboembolic events (p-value<0.001) and cerebrovascular events (p-value=0.007). Dedicated subanalyses revealed that cumulative glucocorticoid dose (p-value=0.010) and a diagnosis of SLE before 2000 (p-value<0.001) were significantly associated with CVE. Cardiovascular disease is highly prevalent among patients with SLE and is associated with antiphospholipid antibodies, glucocorticoid therapy, and diagnosis before 2000.